PolyPeptide Shareholders Approve All Board Proposals at 2026 Annual Meeting

PolyPeptide Group AG announced that shareholders approved all proposals put forward by the Board of Directors at the Company’s fifth annual General Meeting with a large majority. The Chair of the Board of Directors, Peter Wilden, welcomed shareholders at the meeting that took place at the Chollerhalle in Zug. A total of 26,780,855 shares with voting rights were represented, corresponding to 80.85% of the issued registered shares of the Company.

All six members of the Board of Directors proposed for re-election were appointed for a term of office ending at the conclusion of the next annual General Meeting 2027. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term of office ending at the conclusion of the next annual General Meeting 2027. Further proposals of the Board of Directors that were approved included the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee.

The shareholders granted discharge to all members of the Board of Directors and Executive Committee in office in the financial year 2025 for their activities in that year. The shareholders approved the Management Report, Statutory Financial Statements, Consolidated Financial Statements and the report on non-financial matters for the financial year 2025 as well as the Remuneration Report 2025 in a separate consultative vote. The minutes of the AGM 2026 will be available within 15 days on the Company’s website at https://polypeptide.com. The next annual General Meeting 2027 will be held on 7 April 2027.

This shareholder approval matters because it demonstrates strong governance continuity and investor confidence in PolyPeptide’s leadership during a period of significant growth in peptide-based pharmaceuticals. The overwhelming support for all board proposals, including financial reports and compensation structures, indicates alignment between management and shareholders regarding the company’s strategic direction. As a specialized Contract Development & Manufacturing Organization for peptide-based active pharmaceutical ingredients, PolyPeptide operates in a rapidly expanding market with particular exposure to metabolic diseases including GLP-1 therapies. The re-election of experienced board members provides stability as the company navigates increasing demand for peptide manufacturing services. The high shareholder participation rate of over 80% reflects engaged ownership in a company that contributes to global health through peptide-based medicines. The approval of financial statements and discharge of board members suggests satisfactory performance and governance during the previous financial year, which is particularly important for a publicly traded company listed on SIX Swiss Exchange under ticker symbol PPGN.